MFCEM Dialogues #13
by
Dr. Anil Koul,
VP & Head, Global Public Health discovery J&J
on
Title: Discovery of Bedaquiline and Its Impact on the Global TB Landscape
21 February 2025
MFCEM Dialogues & Prof. Arabindo Nath Bose Endowed Lecture by Dr. Anil Koul, VP & Head, Global Public Health discovery, J&J & a member of the Board of Directors of Janssen Pharmaceuticals. Dr. Koul also serves as a Professor of Translational Discovery at the London School of Hygiene and Tropical Medicine and has previously served as Director of the CSIR-Institute of Microbial Technology, Chandigarh.
Dr. Koul spoke about recent efforts in drug discovery for COVID-19 & Dengue, & about the groundbreaking development of Bedaquiline, one of the very few drugs approved for the treatment of drug-resistant tuberculosis in the past several decades. How shared how Bedaquiline has revolutionized TB treatment worldwide.
Dr Koul shared how additional targets within mycobacterial metabolic pathways are being investigated to develop the next generation of TB drugs. And the role of advancements in AI and generative chemistry to accelerate the process.
